4.7 Article

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study

Related references

Note: Only part of the references are listed.
Article Hematology

Development of luspatercept to treat ineffective erythropoiesis

Anne Sophie Kubasch et al.

Summary: Luspatercept, an activin receptor type IIB fusion protein ligand trap, targets the altered transforming growth factor beta pathway in MDS to improve terminal erythroid maturation and alleviate anemia symptoms. Additional studies are needed to better understand the mechanism of action and pharmacodynamics of this novel agent in MDS.

BLOOD ADVANCES (2021)

Article Oncology

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells

Manja Wobus et al.

Summary: This study shows that luspatercept can restore ineffective hematopoiesis in MDS patients by modulating the functional properties of MSCs in the bone marrow microenvironment.

LEUKEMIA (2021)

Article Medicine, General & Internal

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Hematology

Treatment of MDS

Uwe Platzbecker

BLOOD (2019)

Article Hematology

A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers

Kenneth M. Attie et al.

AMERICAN JOURNAL OF HEMATOLOGY (2014)

Article Biochemistry & Molecular Biology

Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

Rajasekhar N. V. S. Suragani et al.

NATURE MEDICINE (2014)

Review Hematology

How we treat lower-risk myelodysplastic syndromes

Pierre Fenaux et al.

BLOOD (2013)